The CIC-backed eye disease treatment developer has filed for a $100m initial public offering, having raised over $250m in funding in the past two years.
Gyroscope Therapeutics, a UK-based developer of treatments for retinal diseases co-founded by University of Cambridge and Syncona, has filed for an initial public offering in the United States.
The company has set a placeholder target of $100m and intends to float on the Nasdaq Global Select Market.
Gyroscope is developing gene therapies for the treatment of eye diseases that cause vision loss or blindness. It was established in 2016 by Syncona and Cambridge Enterprise, the commercialisation arm…
